Keyphrases
A1 Receptor
100%
Type 2 Diabetes Mellitus (T2DM)
100%
Receptor Agonist
100%
Glucagon-like
100%
Glaucoma
100%
Confidence Interval
50%
Hazard Ratio
40%
Low Risk
20%
Birth Timing
20%
Antihyperglycemic
20%
National Cohort Study
10%
Adjusted Hazard Ratio
10%
Treatment Initiation
10%
Metformin
10%
Nested Case-control Study
10%
Conditional Logistic Regression
10%
Agonist Treatment
10%
Surgical Intervention
10%
Second-line Treatment
10%
Free Control
10%
Treatment Other
10%
Time Use
10%
Prolonged Treatment
10%
Eye Injuries
10%
Trauma Surgery
10%
Drug Formulation
10%
Eye Surgery
10%
Incidence Density
10%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Glucagon-Like Peptide-1 Agonist
100%
Glaucoma
100%
Hazard Ratio
50%
Drug Therapy
20%
Childbirth
10%
Logistic Regression Analysis
10%
Glycon
10%
Surgery
10%
Case-Control Study
10%
Eye Injury
10%
Eye Surgery
10%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Glaucoma
100%
Case-Control Study
10%
Metformin
10%
Eye Injury
10%
Drug Formulation
10%
Neuroscience
Glaucoma
100%
Glucagon-Like Peptide-1 Agonist
100%
Metformin
10%